Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD's The Liver Meeting®
Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
Goldgroup Announces Shareholder Approval of Arrangement with Gold Resource Corporation and Results of Annual General and Special Meeting
Freegold Drills 2.08 g/t Au over 62.1 m within 102.3 m of 1.67 g/t Au in Infill Drilling at Golden Summit
Metalsource Mining Expands Silver Hill District Through Strategic Land Acquisition as Exploration Footprint Continues to Grow
